PMEF
PYXS icon

Point72 Middle East FZE’s Pyxis Oncology PYXS Stock Holding History

Point72 Middle East FZE’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,447
Closed -$9.81K – 1979
2023
Q1 		$9.81K Buy
+2,447
New +$4.89K ﹤0.01% 1485

Other funds holding PYXS

LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Middle East FZE's PYXS Position: Q2 2023 in Review

Point72 Middle East FZE sold out of Pyxis Oncology (PYXS) in Q2 2023, closing a stake of 2,447 shares — an estimated $9.81K sold.

Point72 Middle East FZE first reported a position in PYXS in Q1 2023 and held it in 1 quarter. The position peaked at $9.81K in Q1 2023. 48 funds tracked by Wall St. Rank hold PYXS as of Q2 2023.

  • Point72 Middle East FZE reported no remaining Pyxis Oncology position as of Q2 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 2,447 Pyxis Oncology shares in Q2 2023, an estimated $9.81K.
  • Point72 Middle East FZE first reported a position in Pyxis Oncology in Q1 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Pyxis Oncology position peaked at $9.81K in Q1 2023.
  • 48 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2023.

Based on Point72 Middle East FZE's 13F filing for Q2 2023, filed 14 Aug 2023.